Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. (Q42050819)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Marcos González Díaz

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Joaquin Martinez-Lopez

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Joana Caetano

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Łukasz Sędek

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jesús San Miguel

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jacques Van Dongen

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Luzalba Sanoja-Flores

2

object named as

L Sanoja-Flores

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

14

A Corral-Mateos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

31

B Durie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

J Flores-Montero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

B Paiva

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

N Puig

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

O García-Sánchez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

S Böttcher

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

V H J van der Velden

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

J-J Pérez-Morán

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M-B Vidriales

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

C Jimenez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

G-E Grigore

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

R Fluxá

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

R Pontes

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M-C Del Cañizo

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

J Bladé

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

J-J Lahuerta

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

C Aguilar

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

A Bárez

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

A García-Mateo

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

J Labrador

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

P Leoz

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

C Aguilera-Sanz

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M-V Mateos

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

A Orfao

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

publication date

20 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

2094-2103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

9 April 2020

copyright license

start time

20 January 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/leu.2017.29

0 references

cites work

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Deep Response in Multiple Myeloma: A Critical Review

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Assessment of minimal residual disease in myeloma and the need for a consensus approach

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Treatment for patients with newly diagnosed multiple myeloma in 2015.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Promising therapies in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

New criteria for response assessment: role of minimal residual disease in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Curing myeloma at last: defining criteria and providing the evidence

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Initial treatment of transplant-ineligible patients in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Association of response endpoints with survival outcomes in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Overview of clinical flow cytometry data analysis: recent advances and future challenges

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Generation of flow cytometry data files with a potentially infinite number of dimensions.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Selecting fluorochrome conjugates for maximum sensitivity

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Myeloma minimal residual disease testing in the United States: Evidence of improved standardization

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Multiple Myeloma: Diagnosis and Treatment.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5629369

17 August 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.29

7 January 2021

Identifiers

DOI

10.1038/LEU.2017.29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104919%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference